Clin2
NCT06505551Possibly a fitNot yet recruiting

Modified immune cells for HPV-related advanced cancers

HPV-Related Squamous Cell CarcinomaHPV-Related Cervical Squamous Cell CarcinomaHPV-Related Vulvar Squamous Cell CarcinomaHPV-Related Penile Squamous Cell CarcinomaHPV-Related Vaginal Squamous Cell CarcinomaHPV-Related Anal Squamous Cell CarcinomaHPV-Related Head and Neck Cancer

Treatments studied

Part of Cancer, Digestive system, Ear, nose & throat, Kidney & urinary, Mouth & dental, Women’s health & pregnancy clinical trials.

This trial tests a new treatment using your own immune cells (called T cells) that are modified to target HPV-positive cancer cells. It may be an option if you have advanced cervical, head/neck, anal, penile, vulvar, or vaginal cancer that is HPV16 or HPV52 positive and has progressed after standard therapy.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
66 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must have a type of cancer that started in the cervix, head/neck, anus, penis, vulva, or vagina.
  • Your tumor must be positive for HPV type 16 or 52.
  • You must have the HLA-A*02:01 gene type (a blood or tissue test will show this).
  • Your cancer must have spread or come back after at least one standard treatment like chemo or immunotherapy.
  • You must be well enough to be up and about (ECOG score 0 or 1) and have adequate organ function.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05639972Recruiting· Phase 1/Phase 2
HPV cancer trial using immune T cells made for you

This Phase 1/2 trial tests a one-time infusion of special immune T cells made to recognize your HPV16 tumor. It may help your body attack the cancer, while researchers closely monitor safety and early effectiveness.

New Brunswick, New Jersey
NCT05686226Recruiting· Phase 2
Trial tests immune cells targeting HPV-16 cancers

This Phase 2 trial tests an immune-cell treatment (E7 TCR T cells) designed to attack cancers caused by HPV type 16. It may help people whose HPV-16+ cancer has come back or not responded to standard treatment.

Bethesda, Maryland
NCT05582590Not yet recruiting· Phase 1
T-cell therapy for HPV throat cancer after prior treatments

This early-phase study tests a lab-made treatment using your own immune cells (T cells) to target HPV-related throat cancers. It aims to reduce cancer by directing your immune system against HPV16/HPV18 and a protein called survivin.

NCT06544720Recruiting· Phase 1
SCG142 TCR-T cell therapy for HPV-related cancers

This trial tests a new treatment called SCG142 TCR-T cells for cancers caused by HPV. The therapy uses your own immune cells to fight the tumor. It may help if other treatments haven't worked or are not available.

Qingdao, Shandong
NCT06686043Recruiting· Phase 2
HPV vaccine, imiquimod, and metformin for advanced cervical or vulvar cancer

This trial tests a combination of an HPV vaccine, an immune cream (imiquimod), and a diabetes drug (metformin) together with standard chemoradiation. The goal is to see if this mix helps treat advanced cervical, vaginal, or vulvar cancers better than standard care alone.

Houston, Texas
NCT07735065Not yet recruiting· Phase 1
Special immune cells for advanced gastrointestinal cancer

This trial tests a new treatment using your own immune cells that are trained to attack cancer. It is for people with advanced stomach, colon, or esophageal cancer who have already tried other treatments that didn't work.

Hear when a new HPV-Related Squamous Cell Carcinoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.